Autres langues CVRx, Inc.

Actions

CVRX

US1266381052

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
14,39 ^USD	-0,07 %		-5,70 %	-54,23 %

31/01	CVRx, Inc. annonce la nomination de Kevin Hykes au poste de président, à compter du 12 février 2024	CI
31/01	CVRx, Inc. annonce le changement de son directeur général à compter du 12 février 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024	16/04
CVRx announces availability of additional data supporting long-term benefits of Barostim	15/04
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer	31/01
CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12, 2024	31/01
CVRx, Inc. Announces Chief Executive Officer Changes, Effective February 12, 2024	31/01
CVRx Q4 Net Loss Narrows, Revenue Climbs; Q1, Full-Year 2024 Revenue Guidance Set	25/01
CVRx: Q4 Earnings Snapshot	25/01
CVRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25/01
Earnings Flash (CVRX) CVRX Posts Q4 Revenue $11.3M, vs. Street Est of $11.1M	25/01
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	25/01
CVRx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	25/01
CVRx to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call on January 25th, 2024	11/01
CVRx Shares Drop; CEO to Retire; Preliminary Q4, 2023 Revenue Top Consensus; Q1 Forecast Issued	08/01
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans	08/01
CVRx, Inc. Announces Nadim Yared Retires as Chief Executive Officer	08/01
CVRx, Inc. Announces Nadim Yare Retires as President	08/01
CVRx, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023 and First Quarter and Full Year of 2024	08/01
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare Conference	27/12
CVRx receives FDA approval for expanded labeling of BarostimU.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF data	27/12
CVRx Gets FDA Approval for Expanded Labeling for Barostim	26/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues CVRx, Inc.

Actions

CVRX

US1266381052

Autres langues

Filtres